Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
Primary Purpose
Parkinson Disease
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Active Comparator: Active tDCS and Active TUS
Sham Comparator: Sham TDCS and Sham TUS
Physical Therapy
Sponsored by
About this trial
This is an interventional other trial for Parkinson Disease
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of "probable" or "possible" PD, as defined by the current clinical criteria (Gelb D, Oliver E, Gilman S. Diagnostic Criteria for Parkinson's Disease. Arch Neurol.1999;56:33-39) as confirmed by co-investigator neurologist, or confirmation via medical records or a letter from patient physician;
- Complaints about balance impairment or postural instability due to PD (self-report);
- Age from 40 to 90 years old;
- Taking stable medications for PD for at least 30 days.
Exclusion Criteria:
- Features suggestive of other causes of parkinsonism/Parkinson's-plus syndromes;
- History of deep brain stimulation or brain ablation surgeries, malignant mass brain lesions;
- History of schizophrenia, bipolar illness; history of alcohol/drug abuse within the past 6 months;
- Need for rapid clinical response due to conditions such as initiation, psychosis, or suicidality;
- Contraindications to transcranial brain stimulation or TUS, i.e. metal in the head, implanted brain medical devices, etc.;
- Unstable medical conditions (e.g., uncontrolled diabetes, uncompensated cardiac issues, heart failure, uncompensated pulmonary disease, or chronic obstructive pulmonary disease);
- Pregnancy.
- Epilepsy or disorders that significantly increase likelihood of seizures including: severe traumatic brain injury, congenital birth defects leading to seizures, brain tumor, metabolic disorders associated with seizures, intracranial or subarachnoid hemorrhage, and nonlacunar strokes.
- Recent (<= 2 months) or planned enrollment in an additional physician prescribed physical therapy program during their time in the trial.
- Presence of another disorder that might have a significant impact on balance (as assessed by a co-investigator neurologist).
- Bed or wheelchair-bound
Sites / Locations
- Spaulding Rehabilitation Network Research InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Active tDCS and Active TUS
Sham TDCS and Sham TUS
Arm Description
Active tDCS and Active TUS for 20 min
Sham TDCS and Sham TUS for 20 min
Outcomes
Primary Outcome Measures
Change in postural sway
Postural sway will be assessed through biomechanical assessments using a set of integrated sensors including accelerometers, gyroscopes, force sensors, and motion-capture cameras.
Secondary Outcome Measures
Unified Parkinson's Disease Rating Scale (UPDRS)
Motor function (including tremor, bradykinesia, postural instability and gait), non-motor symptoms, activities of daily living and complications of therapy will be investigated per UPDRS (parts I-IV); staging of PD and ability to perform activities of daily living will also be investigated via UPDRS parts V and VI. We already have experience using this assessment in several previous brain stimulation PD studies.
Leg Agility
kinematic changes will be assessed with kinematic metrics (e.g., speed (m/s)) taken with a biomechanical assessment suite throughout the study.
Arising from a chair
kinematic changes will be assessed with kinematic metrics (e.g., time to complete task) taken with a biomechanical assessment suite throughout the study.
Balance
kinematic changes will be assessed with kinematic metrics taken during a modified Romberg exam (e.g., change in center of pressure over a fixed time interval (cm)) with a biomechanical assessment suite throughout the study.
Gait
changes in the walking speed, gait asymmetry, stride length, walking smoothness, and gait freezing kinematic characteristics (e.g., m/s) will be assessed with a biomechanical assessment suite throughout the study
Toe tapping
kinematic changes will be assessed with kinematic metrics (e.g., speed (m/s)) taken with a biomechanical assessment suite throughout the study.
Full Information
NCT ID
NCT03981055
First Posted
January 28, 2019
Last Updated
August 12, 2022
Sponsor
Spaulding Rehabilitation Hospital
Collaborators
Highland Instruments, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT03981055
Brief Title
Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
Official Title
Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 23, 2020 (Actual)
Primary Completion Date
August 1, 2023 (Anticipated)
Study Completion Date
August 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Spaulding Rehabilitation Hospital
Collaborators
Highland Instruments, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
5. Study Description
Brief Summary
This trial aims to understand the mechanism and to test whether transcranial direct current stimulation (tDCS) combined with transcranial ultrasound (TUS) (tDCS+TUS) combined with physical therapy (PT) will induce significant therapeutic effects in postural instability in Parkinson's disease (PT) patients. The investigators designed a double-blinded, placebo controlled, randomized study to investigate the effects of 2 weeks of TDCS+TUS on postural instability in PD patients receiving PT. (Followed by biweekly sessions for 2 more weeks in Phase II)
Detailed Description
Current treatments for Parkinson's Disease (PD), including pharmacological (levodopa) and surgical (DBS) methods, have limited impact on postural instability. Physical therapy (PT) for PD is becoming increasingly used as a means to induce benefits on patient balance. However, limits in efficacy and consistency still exist. In this study, the investigators will test the effects of TDCS+TUS combined with PT on postural instability of PD patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Active tDCS and Active TUS
Arm Type
Experimental
Arm Description
Active tDCS and Active TUS for 20 min
Arm Title
Sham TDCS and Sham TUS
Arm Type
Sham Comparator
Arm Description
Sham TDCS and Sham TUS for 20 min
Intervention Type
Device
Intervention Name(s)
Active Comparator: Active tDCS and Active TUS
Intervention Description
Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Intervention Type
Device
Intervention Name(s)
Sham Comparator: Sham TDCS and Sham TUS
Intervention Description
Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Intervention Type
Other
Intervention Name(s)
Physical Therapy
Intervention Description
All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable. (And during the biweekly sessions for Phase II)
Primary Outcome Measure Information:
Title
Change in postural sway
Description
Postural sway will be assessed through biomechanical assessments using a set of integrated sensors including accelerometers, gyroscopes, force sensors, and motion-capture cameras.
Time Frame
1 week pre intervention, immediately before intervention, following stimulation treatment (stimulation day 5, 10 and 14), and all follow ups
Secondary Outcome Measure Information:
Title
Unified Parkinson's Disease Rating Scale (UPDRS)
Description
Motor function (including tremor, bradykinesia, postural instability and gait), non-motor symptoms, activities of daily living and complications of therapy will be investigated per UPDRS (parts I-IV); staging of PD and ability to perform activities of daily living will also be investigated via UPDRS parts V and VI. We already have experience using this assessment in several previous brain stimulation PD studies.
Time Frame
1 week pre intervention, immediately before intervention, following stimulation treatment (stimulation day 5, 10 and 14), and all follow ups
Title
Leg Agility
Description
kinematic changes will be assessed with kinematic metrics (e.g., speed (m/s)) taken with a biomechanical assessment suite throughout the study.
Time Frame
1 week pre intervention, immediately before intervention, following stimulation treatment (stimulation day 5, 10 and 14), and all follow ups
Title
Arising from a chair
Description
kinematic changes will be assessed with kinematic metrics (e.g., time to complete task) taken with a biomechanical assessment suite throughout the study.
Time Frame
1 week pre intervention, immediately before intervention, following stimulation treatment (stimulation day 5, 10 and 14), and all follow ups
Title
Balance
Description
kinematic changes will be assessed with kinematic metrics taken during a modified Romberg exam (e.g., change in center of pressure over a fixed time interval (cm)) with a biomechanical assessment suite throughout the study.
Time Frame
1 week pre intervention, immediately before intervention, following stimulation treatment (stimulation day 5, 10 and 14), and all follow ups
Title
Gait
Description
changes in the walking speed, gait asymmetry, stride length, walking smoothness, and gait freezing kinematic characteristics (e.g., m/s) will be assessed with a biomechanical assessment suite throughout the study
Time Frame
1 week pre intervention, immediately before intervention, following stimulation treatment (stimulation day 5, 10 and 14), and all follow ups
Title
Toe tapping
Description
kinematic changes will be assessed with kinematic metrics (e.g., speed (m/s)) taken with a biomechanical assessment suite throughout the study.
Time Frame
1 week pre intervention, immediately before intervention, following stimulation treatment (stimulation day 5, 10 and 14), and all follow ups
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of "probable" or "possible" PD, as defined by the current clinical criteria (Gelb D, Oliver E, Gilman S. Diagnostic Criteria for Parkinson's Disease. Arch Neurol.1999;56:33-39) as confirmed by co-investigator neurologist, or confirmation via medical records or a letter from patient physician;
Complaints about balance impairment or postural instability due to PD (self-report);
Age from 40 to 90 years old;
Taking stable medications for PD for at least 30 days.
Exclusion Criteria:
Features suggestive of other causes of parkinsonism/Parkinson's-plus syndromes;
History of deep brain stimulation or brain ablation surgeries, malignant mass brain lesions;
History of schizophrenia, bipolar illness; history of alcohol/drug abuse within the past 6 months;
Need for rapid clinical response due to conditions such as initiation, psychosis, or suicidality;
Contraindications to transcranial brain stimulation or TUS, i.e. metal in the head, implanted brain medical devices, etc.;
Unstable medical conditions (e.g., uncontrolled diabetes, uncompensated cardiac issues, heart failure, uncompensated pulmonary disease, or chronic obstructive pulmonary disease);
Pregnancy.
Epilepsy or disorders that significantly increase likelihood of seizures including: severe traumatic brain injury, congenital birth defects leading to seizures, brain tumor, metabolic disorders associated with seizures, intracranial or subarachnoid hemorrhage, and nonlacunar strokes.
Recent (<= 2 months) or planned enrollment in an additional physician prescribed physical therapy program during their time in the trial.
Presence of another disorder that might have a significant impact on balance (as assessed by a co-investigator neurologist).
Bed or wheelchair-bound
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Felipe Fregni, MD, PhD
Phone
6179526158
Email
Fregni.Felipe@mgh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Elly Pichardo, MD
Phone
617-952-6154
Email
epichardo@partners.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Felipe Fregni, MD, PhD
Organizational Affiliation
Spaulding Rehabilitation Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Spaulding Rehabilitation Network Research Institute
City
Charlestown
State/Province
Massachusetts
ZIP/Postal Code
02129
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Felipe Fregni, MD PhD MPH
Phone
617-952-6156
Email
ffregni@partners.org
First Name & Middle Initial & Last Name & Degree
Elly Pichardo, MD
Phone
617-952-6154
Email
epichardo@partners.org
First Name & Middle Initial & Last Name & Degree
Felipe Fregni, MD PhD MPH
12. IPD Sharing Statement
Learn more about this trial
Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
We'll reach out to this number within 24 hrs